DrIndy Sandaradura

Digital Health, Antimicrobial Pharmacology, Antimicrobial Resistance, Novel Therapies

 

 

 

Dr Sandaradura's research programme encompasses three interconnected themes:

 

• Therapeutic Drug Monitoring and Precision Dosing: Developing population pharmacokinetic models and Bayesian dosing strategies for antibiotics and antifungals in special populations including critically ill adults, paediatric patients, and those with cystic fibrosis. Notable contributions include model-optimized fluconazole dosing that eliminates the need for therapeutic drug monitoring and novel vancomycin dosing strategies in paediatric intensive care.

 

• Antimicrobial Resistance Epidemiology and Genomics: Conducting genomic surveillance of multidrug-resistant organisms with emphasis on extended-spectrum beta-lactamase and carbapenemase-producing Enterobacteriaceae. Recent work includes characterizing OXA-48/CTX-M-15 Klebsiella pneumoniae clusters in intensive care and contributing to international genomic analyses of extensively drug-resistant Shigella sonnei.

 

• Digital Health and Clinical Informatics: Implementing artificial intelligence and clinical decision support systems to optimize antimicrobial prescribing. Research includes evaluating barriers to therapeutic drug monitoring implementation in Australian hospitals and redesigning computerized decision support to improve antimicrobial prescribing practices.